DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Items 201–300 of 1,000
Andersen, M. G., Thorsted, A., Storgaard, M., Kristoffersson, A., Friberg, L. E., & Öbrink‐Hansen, K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02306-17 · Cited by 42
Wu, C., Tai, C.-H., Liao, W.-Y., Wang, C., Kuo, C., Lin, S., & Ku, S. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s213183 · Cited by 42
Öbrink‐Hansen, K., Juul, R. V., Storgaard, M., Thomsen, M. K., Hardlei, T. F., Brock, B., Kreilgaard, M., & Gjedsted, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01347-15 · Cited by 48
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections
Al‐Shaer, M. H., Maranchick, N. F., Alexander, K. M., Manigaba, K., Shoulders, B. R., Felton, T., Mathew, S. K., & Peloquin, C. A. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106727 · Cited by 41
Individualized antibiotic dosage regimens for patients with augmented renal clearance
Shi, A., Qu, Q., Zhuang, H.-H., Teng, X.-Q., Xu, W.-X., Liu, Y., Xiao, Y., & Qu, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1137975 · Cited by 43
Cies, J. J., Moore, W. S., Dickerman, M. J., Small, C., Carella, D. M., Chopra, A., & Parker, J. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1476 · Cited by 41
Bergen, P. J., Bulitta, J. B., Kirkpatrick, C. M. J., Rogers, K. E., McGregor, M. J., Wallis, S. C., Paterson, D. L., Lipman, J., Roberts, J. A., & Landersdorfer, C. B. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw153 · Cited by 41
Self-citationWoksepp, H., Hällgren, A., Borgström, S., Kullberg, F., Wimmerstedt, A., Oscarsson, A., Nordlund, P., Lindholm, M.-L., Bonnedahl, J., Brudin, L. H., et al. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2832-4 · Cited by 45
Waele, J. J. D., & Dhaese, S. A. M. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1568239 · Cited by 47
“This may lead to antibiotic underdosing which has been linked to clinical failure [24,78].”
BackgroundPopulation Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients
Saito, J., Shoji, K., Oho, Y., Kato, H., Matsumoto, S., Aoki, S., Nakamura, H., Ogawa, T., Hasegawa, M., Yamatani, A., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01909-20 · Cited by 45
Goncette, V., Layios, N., Descy, J., & Frippiat, F. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.015 · Cited by 41
Lanckohr, C., Boeing, C., Waele, J. J. D., de Lange, D. W., Schouten, J. A., Prins, M. W. J., Nijsten, M. W., Póvoa, P. M. S. R., Morris, A. C., & Bracht, H. (2021) · Annals of Intensive Care · doi:10.1186/s13613-021-00917-2 · Cited by 44
“Standard dosing regimens for many antimicrobials were shown to be associated with extremely variable drug levels [11], potentially causing unacceptable rates of underdosing and adverse outcomes [12, 13].”
BackgroundDo antibiotics cause mitochondrial and immune cell dysfunction? A literature review
Khpal, M., & Singer, M. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac025 · Cited by 41
Cock, P. A. J. G. D., Mulla, H., Desmet, S., Somer, F. M. J. J. D., McWhinney, B. C., Ungerer, J. P. J., Moerman, A., Commeyne, S., Walle, J. V., François, K., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw496 · Cited by 46
Klebsiella pneumoniae liver abscesses: pathogenesis, treatment, and ongoing challenges
Angeles-Solano, M., Tabashsum, Z., Chen, L., & Rowe, S. E. (2025) · Infection and Immunity · doi:10.1128/iai.00508-24 · Cited by 45
Delivering precision antimicrobial therapy through closed-loop control systems
Rawson, T. M., O’Hare, D., Herrero, P., Sharma, S., Moore, L. S. P., de Barra, E., Roberts, J. A., Gordon, A. C., Hope, W. W., Georgiou, P., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx458 · Cited by 42
Self-citationAbdulla, A., Ewoldt, T. M. J., Purmer, I. M., Muller, A. E., Gommers, D. A. M. P. J., Endeman, H., & Koch, B. C. P. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1879049 · Cited by 44
“However, 100% ƒT > MIC target attainment is reported in only 40% to 60% of critically ill patients treated with β-lactam antibiotics [5,19,53].”
BackgroundJain, M., Stitt, G. A., Son, L., & Enioutina, E. Y. (2023) · Microorganisms · doi:10.3390/microorganisms11102393 · Cited by 45
Neugebauer, S., Wichmann, C., Bremer-Streck, S., Hagel, S., & Kiehntopf, M. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000570 · Cited by 39
Dietl, B., Martínez, L. M., Calbo, E., & Garau, J. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0012 · Cited by 39
Personalized antibiotic dosing for the critically ill
Roberts, J. A., Roger, C., & Waele, J. J. D. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05522-3 · Cited by 42
Self-citationChua, N. G. S., Loo, L., Hee, D. K.-H., Lim, T.-P., Ng, T. M., Hoo, G. S. R., Soong, J. L., Ong, J. C. L., Tang, S. S. L., Zhou, Y. P., et al. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.12.013 · Cited by 38
Kipper, K., Barker, C. I. S., Standing, J. F., Sharland, M., & Johnston, A. E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01540-17 · Cited by 39
Braune, S. A., König, C., Roberts, J. A., Nierhaus, A., Steinmetz, O. M., Baehr, M., Kluge, S., & Langebrake, C. (2018) · Critical Care · doi:10.1186/s13054-018-1940-1 · Cited by 38
Self-citationLiu, M., Yang, Z., & Li, G. (2018) · Molecules · doi:10.3390/molecules23112939 · Cited by 38
“Many studies have shown that the kidneys show a persistent increase in glomerular filtration rate in diabetic patients, ranged from 20 to 30%, and in some untreated diabetic patients may be as high as 30 to 40% [45].”
BackgroundGrégoire, M., Dailly, É., Turnier, P. L., Garot, D., Guimard, T., Bernard, L., Tattevin, P., Vandamme, Y.-M., Hoff, J., Lemaitre, F., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00634-19 · Cited by 44
Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
Abdulla, A., Rogouti, O., Hunfeld, N., Endeman, H., Dijkstra, A., van Gelder, T., Muller, A. E., de Winter, B. C. M., & Koch, B. C. P. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02873-5 · Cited by 42
Landersdorfer, C. B., & Nation, R. L. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2203 · Cited by 41
Bakdach, D., Elajez, R., Bakdach, A. R., Awaisu, A., PASCALE, G. D., & Hssain, A. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236898 · Cited by 43
Abdul-Aziz, M. H., Portunato, F., & Roberts, J. A. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000681 · Cited by 38
“critically ill and immunocompromised patients) commonly develop extreme pathophysiological changes that can significantly reduce antibiotic exposure, particularly when intermittent infusion dosing is used [15,45].”
BackgroundSelf-citationAugmented renal clearance and therapeutic monitoring of β-lactams
Udy, A. A., Waele, J. J. D., & Lipman, J. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.12.020 · Cited by 37
Self-citationRadovanovic, M., Day, R. O., Jones, G. R. D., Galettis, P., & Norris, R. L. G. (2022) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2022.11.001 · Cited by 40
“The literature indicates a relationship between serum concentrations of β-lactams and clinical outcomes in the critically ill [9], making TDM a potentially useful tool for dose optimization of this class of drugs.”
Carrié, C., Bentejac, M., Cottenceau, V., Masson, F., Petit, L., Cochard, J.-F., & Sztark, F. (2017) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2017.06.006 · Cited by 44
Bellouard, R., Deslandes, G., Morival, C., Li, J., Boutoille, D., Jolliet, P., Dailly, É., & Grégoire, M. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112904 · Cited by 36
Roggeveen, L. F., Fleuren, L. M., Guo, T., Thoral, P., de Grooth, H., Swart, E. L., Klausch, T. L. T., van der Voort, P. H. J., Girbes, A. R. J., Bosman, R. J., et al. (2019) · Trials · doi:10.1186/s13063-019-3911-5 · Cited by 38
“studies [10], this paucity of data sharply contrasts the widespread adoption of therapeutic drug monitoring”
BackgroundInfluentialPetersson, J., Giske, C. G., & Eliasson, E. (2016) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12808 · Cited by 36
Bos, J. C., Prins, J. M., Mistício, M. C., Nunguiane, G., Lang, C. N., Beirão, J. C., Mathôt, R. A. A., & van Hest, R. M. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky071 · Cited by 36
Beganovic, M., McCreary, E. K., Mahoney, M. V. G., Dionne, B., Green, D. A., & Timbrook, T. T. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.026450 · Cited by 38
Rizk, N., Kanafani, Z. A., Tabaja, H., & Kanj, S. S. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1348894 · Cited by 36
“In 20% of the patients, the minimum conservative PK/PD target of 50% fT > MIC was not achieved [37].”
BackgroundInfluentialMachado, A. S., de Oliveira, M. S., Sanches, C., da Silva, C. V., Gomez, D. D. S., Gemperli, R., Santos, S. R. C. J., & Levin, A. S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.008 · Cited by 35
Bakterielle Sepsis: Diagnostik und kalkulierte Antibiotikatherapie
Richter, D., Heininger, A., Brenner, T., Hochreiter, M., Bernhard, M., Briegel, J., Dubler, S., Grabein, B., Hecker, A., Krüger, W. A., et al. (2017) · Der Anaesthesist · doi:10.1007/s00101-017-0363-8 · Cited by 37
Silva, C. M., Baptista, J. P., Santos, I., & Martins, P. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106569 · Cited by 39
Self-citationAl‐Shaer, M. H., Maranchick, N. F., Bai, C., Maguigan, K. L., Shoulders, B. R., Felton, T., Mathew, S. K., Mardini, M., & Peloquin, C. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-22 · Cited by 35
Stašek, J., Keller, F., Kočí, V., Klučka, J., Klabusayová, E., Wiewiorka, O., Strašilová, Z., Beňovská, M., Škardová, M., & Maláska, J. (2023) · Antibiotics · doi:10.3390/antibiotics12030568 · Cited by 42
“At present, the measurement of plasmatic beta-lactam concentrations should be considered in patients with sepsis, patients with pneumonia and in patients infected with Gram-negative pathogens and with bacteria with decreased susceptibility [9,15,142].”
BackgroundInfluentialTherapeutic drug monitoring: linezolid too?
Richards, G. A., & Brink, A. J. (2014) · Critical Care · doi:10.1186/s13054-014-0525-x · Cited by 35
Chung, E. K., Cheatham, S. C., Fleming, M. R., Healy, D. P., & Kays, M. B. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.812 · Cited by 35
Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study
Denisuik, A. J., Garbutt, L. A., Golden, A., Adam, H. J., Baxter, M. R., Nichol, K. A., Lagacé-Wiens, P. R. S., Walkty, A. J., Karlowsky, J. A., Hoban, D. J., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky477 · Cited by 35
Moniz, P., Coelho, L., & Póvoa, P. M. S. R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01558-w · Cited by 38
“first demonstrated that prolonged infusions of beta-lactams led to higher drug concentrations (100% fT[MIC) and consequently higher likelihood of a positive clinical outcome [7].”
BackgroundMethodInfection, Sepsis and the Inflammatory Response: Mechanisms and Therapy
Lonsdale, D., Shah, R. V., & Lipman, J. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.588863 · Cited by 35
Self-citationMatusik, É., Boidin, C., Friggeri, A., Richard, J., Bitker, L., Roberts, J. A., & Goutelle, S. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000941 · Cited by 37
Self-citationUse of therapeutic drug monitoring to characterize cefepime‐related neurotoxicity
Venugopalan, V., Casaus, D. V., Kainz, L., Slaton, C. N., Hurst, N., Bruzzone, M., Hu, C., Sword, G., Cherabuddi, K., Iovine, N. M., et al. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2744 · Cited by 35
Novy, E., Martinière, H., & Roger, C. (2023) · Antibiotics · doi:10.3390/antibiotics12040681 · Cited by 35
“In critically ill patients, 100% of the time where the free concentration is above the MIC (100% fT > MIC) is often suggested as a therapeutic target [7,10].”
BackgroundDorofaeff, T., Bandini, R. M., Lipman, J., Ballot, D. E., Roberts, J. A., & Parker, S. L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.07.093 · Cited by 34
Self-citationFan, S. G., Shum, H., Cheng, W., Chan, Y.-H., Leung, S., & Yan, W. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1875 · Cited by 34
“A prospective, multinational, pharmacokinetic point-prevalence study, which examined b-lactam antibiotic dosing in critically ill patients, showed that 16% did not achieve 50% CfT > MIC, and these patients were 32% less likely to have a positive clinical outcome.(6) Further studies have lent support to the clinical ef…”
BackgroundLeegwater, E., Kraaijenbrink, B. V. C., Moes, D. J. A. R., Purmer, I. M., & Wilms, E. B. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa067 · Cited by 34
Rhodes, N. J., MacVane, S. H., Kuti, J. L., & Scheetz, M. H. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu402 · Cited by 34
“We applaud the work by Roberts et al that was recently published in the Journal [1].”
BackgroundInfluentialDeutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00671-6 · Cited by 37
Tannous, E. E., Lipman‐Arens, S., Tonna, A. P., Hector, E. E., Hussein, Z., Stein, M., & Reisfeld, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02571-19 · Cited by 33
“In the DALI study, achieving a %fT MIC of 50% and %fT MIC of 100% was associated with improved clinical outcomes (24).”
BackgroundInfluentialAbdulla, A., van den Broek, P., Ewoldt, T. M. J., Muller, A. E., Endeman, H., & Koch, B. C. P. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000937 · Cited by 33
Morales, R., Pereira, G. O., Tiguman, G. M. B., Juodinis, V. D., Telles, J. P., de Souza, D. C., & Santos, S. R. C. J. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.777854 · Cited by 33
“The DALI study, a multinational point-prevalence study with beta-lactams, also found that adult patients achieving 100% fT> MIC are more likely to have positive clinical outcomes with lower levels of sickness severity (33).”
BackgroundTabah, A., Lipman, J., Barbier, F., Buetti, N., Timsit, J., & on behalf of the ESCMID Study Group for Infections in Critically Ill Patients—ESGCIP (2022) · Antibiotics · doi:10.3390/antibiotics11030362 · Cited by 39
“They have an increased volume of distribution (Vd) leading to a lower-than-expected maximum serum concentration during a dosing interval (Cmax) [61].”
BackgroundSelf-citationGonçalves-Pereira, J., Fernandes, J., Duarte, A. R., & Fernandes, S. M. (2022) · Antibiotics · doi:10.3390/antibiotics11121839 · Cited by 40
A three-level model for therapeutic drug monitoring of antimicrobials at the site of infection
Brasier, N., Ates, H. C., Sempionatto, J. R., Cotta, M. O., Widmer, A. F., Eckstein, J., Goldhahn, J., Roberts, J. A., Gao, W. F., & Dincer, C. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00215-3 · Cited by 35
Self-citationCies, J. J., Moore, W. S., Conley, S. B., Dickerman, M. J., Small, C., Carella, D. M., SHEA, P. A., Parker, J., & Chopra, A. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.1.92 · Cited by 33
The use and risks of antibiotics in critically ill patients
Denny, K. J., Cotta, M. O., Parker, S. L., Roberts, J. A., & Lipman, J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1164690 · Cited by 33
Self-citationAhmed, N., Jen, S.-P. P., Altshuler, D., Papadopoulos, J., Pham, V. P., & Dubrovskaya, Y. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618784264 · Cited by 33
“137 LOS in hospital prior to meropenem 3 (1-7) 2 (1-8) 2 (1-7) .”
InfluentialPharmacokinetic variability of beta-lactams in critically ill patients: A narrative review
Boidin, C., Moshiri, P., Dahyot‐Fizelier, C., Goutelle, S., & Lefeuvre, S. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.07.016 · Cited by 33
Lertwattanachai, T., Montakantikul, P., Tangsujaritvijit, V., Sanguanwit, P., Sueajai, J., Auparakkitanon, S., & Dilokpattanamongkol, P. (2020) · Journal of Intensive Care · doi:10.1186/s40560-020-00442-7 · Cited by 35
Roggeveen, L. F., Guo, T., Driessen, R. H., Fleuren, L. M., Thoral, P., van der Voort, P. H. J., Girbes, A. R. J., Bosman, R. J., & Elbers, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00646 · Cited by 35
“The last decade has witnessed repeated calls for more personalized antibiotic dosing regimens (Samtani et al., 2010; Roberts et al., 2014a; Cotta et al., 2015; Tängdén et al., 2017; Roberts et al., 2019).”
BackgroundResultInfluentialFleuren, L. M., Roggeveen, L. F., Guo, T., Waldauf, P., van der Voort, P. H. J., Bosman, R. J., Swart, E. L., Girbes, A. R. J., & Elbers, P. W. G. (2019) · Critical Care · doi:10.1186/s13054-019-2438-1 · Cited by 32
Yang, N., Wang, J., Xie, Y., Ding, J., Wu, C., Liu, J., & Pei, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838205 · Cited by 32
Tanaka, R. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00425-6 · Cited by 32
“This result was comparable to other previous studies reporting 40–45% [15, 16, 17].”
Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients
Turner, R. B., Cumpston, A., Sweet, M. A., Briggs, F., Slain, D., Wen, S., Craig, M., Hamadani, M., & Petros, W. P. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02010-15 · Cited by 32
Heffernan, A. J., Sime, F. B., Sun, J., Lipman, J., Kumar, A., Andrews, K. T., Ellwood, D. A., Grimwood, K., & Roberts, J. A. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.10.020 · Cited by 32
Self-citationDhaese, S. A. M., Heffernan, A. J., Liu, D. C., Abdul-Aziz, M. H., Stove, V. V., Tam, V. H., Lipman, J., Roberts, J. A., & Waele, J. J. D. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00919-6 · Cited by 32
Self-citationLonsdale, D., Kipper, K., Baker, E. H., Barker, C. I. S., Oldfield, I., Philips, B. J., Johnston, A. E., Rhodes, A., Sharland, M., & Standing, J. F. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa363 · Cited by 32
Self-citationWicha, S. G., Mair, A., Chiriac, U., Frey, O. R., Fuchs, T., Gaasch, M., Hagel, S., Richter, D., Roberts, J. A., Röhr, A. C., et al. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106572 · Cited by 32
Self-citationMulticenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients
Heffernan, A. J., Sime, F. B., Kumta, N., Wallis, S. C., McWhinney, B. C., Ungerer, J. P. J., Wong, G. Y. M., Joynt, G. M., Lipman, J., & Roberts, J. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02189-21 · Cited by 32
Self-citationExtended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review
Venuti, F., Trunfio, M., Märtson, A., Lipani, F., Audagnotto, S., Perri, G. D., & Calcagno, A. (2023) · Drugs · doi:10.1007/s40265-023-01893-6 · Cited by 32
Séraissol, P., Lanot, T., Baklouti, S., Mané, C., Ruiz, S., Lavit, M., Riols, P. D., Garrigues, J., & Gandia, P. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4042169 · Cited by 32
Antimicrobial dosing in critical care: A pragmatic adult dosing nomogram
Williams, P. G., Beall, G., Cotta, M. O., & Roberts, J. A. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.10.018 · Cited by 32
Self-citationSong, X., Wu, Y. P., Cao, L., Yao, D., & Long, M. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02777 · Cited by 31
Cortegiani, A., Antonelli, M. M., Falcone, M., Giarratano, A., Girardis, M., Léone, M., Pea, F., Stefani, S., Viaggi, B., & Viale, P. (2023) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-023-00095-6 · Cited by 34
Self-citationWong, G., Farkas, A., Sussman, R., Daróczi, G., Hope, W. W., Lipman, J., & Roberts, J. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04001-14 · Cited by 31
“Selecting the correct dose is as important, but this process is highly challenging in critically ill patients because of the variable and difficult-to-predict pharmacokinetics in these patients (1, 2).”
BackgroundSelf-citationImani, S., Buscher, H., Day, R. O., Gentili, S., Jones, G. R. D., Marriott, D., Norris, R. L. G., & Sandaradura, I. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3357-9 · Cited by 31
Mader, M. M.-D., Czorlich, P., König, C., Fuhrmann, V., Kluge, S., Westphal, M., & Grensemann, J. (2018) · Acta Neurochirurgica · doi:10.1007/s00701-018-3680-z · Cited by 30
Zou, L., Meng, F., Hu, L., Huang, Q., Liu, M., & Yin, T. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.01.039 · Cited by 30
Johnston, B. W., Perry, D., Habgood, M., Joshi, M., & Krige, A. (2021) · Journal of International Medical Research · doi:10.1177/03000605211015573 · Cited by 30
Gijsen, M., Elkayal, O., Annaert, P., Daele, R. V., Meersseman, P., Debaveye, Y. A., Wauters, J., Dreesen, E., & Spriet, I. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s343264 · Cited by 30
Self-citationTimsit, J., Wicky, P.-H., & de Montmollin, É. (2022) · Antibiotics · doi:10.3390/antibiotics11020144 · Cited by 30
“Consequently, antibiotic treatment underdosing is frequent, with up to 65% of critically ill patients receiving β-lactams not achieving maximal bacterial killing [76].”
BackgroundRight dose, right now: using big data to optimize antibiotic dosing in the critically ill
Elbers, P. W. G., Girbes, A., Malbrain, M. L., & Bosman, R. (2015) · Anestezjologia Intensywna Terapia · doi:10.5603/ait.a2015.0061 · Cited by 28
Klastrup, V., Thorsted, A., Storgaard, M., Christensen, S., Friberg, L. E., & Öbrink‐Hansen, K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02556-19 · Cited by 30
Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU
Bassetti, M., Poulakou, G., & Timsit, J. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4341-4 · Cited by 31
Self-citationThabet, P., Joshi, A., MacDonald, E., Hutton, B., Cheng, W., Stevens, A., & Kanji, S. (2021) · PLOS ONE · doi:10.1371/journal.pone.0244966 · Cited by 29
Lockowitz, C. R., Hsu, A. J., Chiotos, K., Bio, L. L., Dassner, A. M., Gainey, A. B., Girotto, J. E., Iacono, D. E., Morrisette, T., Stimes, G. T., et al. (2025) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaf004 · Cited by 29
Heffernan, A. J., Sime, F. B., Taccone, F. S., & Roberts, J. A. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000494 · Cited by 30
Self-citationGijsen, M., Dreesen, E., Annaert, P., Nicolaï, J., Debaveye, Y. A., Wauters, J., & Spriet, I. (2021) · Microorganisms · doi:10.3390/microorganisms9061310 · Cited by 29
Self-citationMaguigan, K. L., Al‐Shaer, M. H., & Peloquin, C. A. (2021) · Antibiotics · doi:10.3390/antibiotics10101154 · Cited by 29
“Thus, in patients with risk factors for beta-lactam toxicities and less-susceptible pathogens, it may be prudent to target alternative PK/PD targets, such as 100% fT > MIC [91].”
BackgroundOptimization of antimicrobial prescription in the hospital
Vieceli, T., & Rello, J. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.08.035 · Cited by 29
Self-citationCommunity-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae
Khatri, A., Murphy, N. N., Wiest, P. M., Osborn, M. K., Garber, K., Hecker, M. T., Hurless, K. N., Rudin, S. D., Jacobs, M. R., Kalayjian, R. C., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00553-15 · Cited by 29
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.